Opinion|Videos|January 2, 2025
Understanding Ruxolitinib’s Mechanism of Action in Atopic Dermatitis
Author(s)Omar Noor, MD, FAAD
The panelist discusses how ruxolitinib treats atopic dermatitis by inhibiting Janus kinase (JAK)1/JAK2 signaling pathways to reduce inflammation and alleviate symptoms of the skin condition.
Advertisement
Episodes in this series
Advertisement
Related to this article
The merger, backed by an oversubscribed $180 million private placement, will fund development of NOR-101, an IL-13 x IL-18 bispecific antibody entering phase 1 trials in atopic dermatitis in early 2027.
Dermatitis-related adverse events vary widely across atopic dermatitis systemic trials, driven by disease fluctuation and reporting differences, informing patient counseling and flare definitions.
New review explores why eczema and ADHD often overlap in youth, highlighting sleep loss, itch-driven inflammation, plus screening and treatment tips.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Advertisement
Advertisement
Trending on Dermatology Times
1
ORKA-001 Achieves Deepening Skin Clearance Through Week 28 in Plaque Psoriasis
2
FAQ: Everything Clinicians (and Their Patients) Want to Know About the Hair Loss Pipeline
3
IMVT-1402 Misses Primary Endpoint in Cutaneous Lupus Proof-of-Concept Trial
4
Barzolvolimab Achieves All Phase 3 End Points in Chronic Spontaneous Urticaria
5